Efficacy of Sofosbuvir and Ledipasvir in Comparison to Sofosbuvir and Daclatasvir in Management of Egyptian Chronic Hepatitis C Patients
Afro-Egypt. j. infect. enem. dis
; 10(2): 163-173, 2022. tables, figures
Artigo
em Inglês
| AIM
| ID: biblio-1426649
Biblioteca responsável:
CG1.1
ABSTRACT
In Egypt, the prevalence of hepatitis C virus (HCV) antibodies is the highest worldwide by 7.6%. Applying efficient treatment protocol on large scale could decrease HCV prevalence as well as disease burden.The aim of this study is to compare the efficacy of Sofosbuvir plus ledipasvir versus Sofosbuvir plus daclatasvir in management of chronic hepatitis C Egyptian patients with either easy to treat (naive patients with Child score A5)or difficult to treat (interferon experienced).
Texto completo:
DisponíveL
Índice:
AIM (África)
Assunto principal:
Resultado do Tratamento
/
Hepatite C Crônica
Tipo de estudo:
Guia de Prática Clínica
/
Estudo observacional
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Afro-Egypt. j. infect. enem. dis
Ano de publicação:
2022
Tipo de documento:
Artigo
Instituição/País de afiliação:
2 Hepatology , Gastroenterology and Infectious Diseases Department ,Faculty f o of Medicine for Girls, AL-Azhar/EG
/
Hepatology , Gastroenterology and Infectious Diseases Department ,Faculty f o of Medicine for Girls/EG
/
Tropical Medicine Department , National Hepatology and Tropical Medicine R R Research Institute/EG
Similares
MEDLINE
...
LILACS
LIS